Presentations & Publications
Explore scientific presentations and publications about our investigational programs.
October 2026 Poster
ACR Convergence
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Afimetoran, an Oral, Once-Daily Equipotent TLR 7/8 Inhibitor, in Participants with Active Systemic Lupus Erythematosus
October 2026 Poster
ACR Convergence
Afimetoran, an Oral Equipotent Dual Antagonist of Toll-Like Receptor 7 (TLR7) and TLR8, in Combination with an Anti-TNF Results in Increased Efficacy in a Collagen-Induced Arthritis Model
October 2026 Poster
ACR Convergence
TLR7/8 Blockade by BMS-905, a Structural Analog of Afimetoran, Drives Transcriptional Rewiring of Kidney Inflammation in a Mouse Model of SLE
July 2026 Publication
ACR Open Rheumatol
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll-Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
November 2024 Poster
ACR Convergence
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
October 2024 Poster
Fall Clinical Dermatology Conference
Pharmacodynamic effects and exploratory efficacy of afimetoran, a TLR7/8 inhibitor, in patients with cutaneous lupus erythematosus
On this page you may select links to key publications from peer-reviewed journals as well as to materials presented at scientific conferences relating to either research studies involving Beeline’s investigational product candidates or to the science guiding our research and development efforts. The safety and efficacy of any investigational product discussed in these materials has yet to be determined. Note that certain of these materials were authored by unaffiliated third parties and do not represent Beeline’s views. The content of each work is the property of the respective copyright holder and may not be further distributed without their express permission. The information in these materials may not be current or comprehensive, and Beeline undertakes no obligation to correct or update such information.
